Bambusa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing a portfolio of next-generation, multi-targeting medicines designed to transform patient care across chronic immunology and inflammation diseases. The company was founded by Shan Shan Xu, Thang Ho, and Helmut Jeggle on March 14, 2024 and is headquartered in Boston, MA.
前日終値
$14.99
−$1.01 · -6.31%
日中の時刻はETです。市場データは遅延する場合があります。
Bambusa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing a portfolio of next-generation, multi-targeting medicines designed to transform patient care across chronic immunology and inflammation diseases. The company was founded by Shan Shan Xu, Thang Ho, and Helmut Jeggle on March 14, 2024 and is headquartered in Boston, MA.
日中レンジ
現在 $14.99
52週レンジ
現在 $14.99
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
